Neoadjuvant Dose-dense EC Followed by ABX With PD-1 for Triple Negative Breast Cancer Patients (NeoTENNIS)

Fudan University

Status and phase

Active, not recruiting

Phase 2

Conditions

Triple Negative Breast Cancer

Treatments

Drug: Albumin bound paclitaxel

Drug: Cyclophosphamide

Drug: Toripalimab

Drug: epirubicin hydrochloride

Study type

Interventional

Funder types

Other

Identifiers

NCT04418154

SCHBCC-N027

Details and patient eligibility

About

This study is to evaluate the efficacy and safety for dose-dense epirubicin hydrochloride with cyclophosphamide followed by nanoparticlealbumin-bound paclitaxel with PD-1 in neoadjuvant therapy for patients with triple-negative breast cancer, and to explore the predictive value of biological markers for the treatment.

Full description

This study is an open single arm study, which would undergo optimal two stage designs. 60 patients who are diagnosed with triple-negative breast cancer would have dose-dense epirubicin hydrochloride with cyclophosphamide followed by nanoparticlealbumin-bound paclitaxel with PD-1 regimen for neoadjuvant therapy if they meet the eligibility criteria. The regimen is as follows: epirubicin hydrochloride (90mg/m2, d1) plus cyclophosphamide (600mg/m2, d1) every 14 days as one cycle for 4 cycles, followed by nanoparticlealbumin-bound paclitaxel (125mg/m2, d1) per week for 3 weeks as one cycle for 4 cycles, and Toripalimab (240mg, d1) every 3 weeks as one cycle for 4 cycles. pathological complete response would be the primary endpoint. The change of biological markers and safety of the regimen would also be evaluated.

Enrollment

70 patients

Sex

Female

Ages

18 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Age 18 to 70 years old, female.
Patients with histologically confirmed unilateral primary invasive breast cancer who meet the criteria of cT2-4NanyM0.
Patients with ER negative and PR negative by immunohistochemistry (IHC), and HER-2 negative disease. HER2-negative disease was defined as follows: disease whose HER-2 is 1+ or negative by IHC, or fluorescence in situ hybridization (FISH) is negative if IHC is 2+.
According to the RECIST 1.1 criteria, there is at least one measurable objective lesion.
Eastern Cooperative Oncology Group (ECOG) performance score 0-1.
Baseline left ventricular ejection fraction (LVEF) is greater than or equal to (>/=) 55%.
Bone marrow function is required as follows: neutrophils are more than or equal to (>/=) 1.5×109/L, platelets more than or equal to (>/=) 100×109/L, and hemoglobin more than or equal to (>/=) 90g/L.
Hepatic and renal function are required as follows: serum creatinine is less than or equal to (</=) 1.5 times of upper limits of normal (ULN), aspartate transaminase (AST) and alanine aminotransferase (ALT) less than or equal to (</=) 2.5 times of ULN, and total bilirubin less than or equal to (</=) 1.5 times of ULN or </= 2.5 times of ULN if patient is with Gilbert's syndrome.
With good compliance with the planned treatment, are able to understand the follow-up procedures of this study and sigh the informed consent form.

Signed informed consent.

Exclusion criteria

Received radiotherapy, chemotherapy, surgery or other targeted and immunotherapy for triple-negative breast cancer before enrollment.
With heart disease classified as New York Heart Association class (NYHA) grade II or above (including grade II) are identified by the investigator.
With severe systemic infection or those with other serious illnesses.
Known to be allergic or intolerant to chemotherapy drugs or their excipients.
With a history of autoimmune diseases or those using glucocorticoids or immunosuppressive drugs.
With known active stage of HBV or HCV infection or hepatitis B DNA ≥500, or patients with chronic abnormal liver function.
With a history of abnormal thyroid function.
With grade ≥ 2 peripheral neuropathy.
With a clear history of neurological or mental disorders, including epilepsy or dement.
Previous non-breast malignancy within 5 years prior to study entry excluding healed cervical carcinoma in situ and non-melanoma skin cancer.
History of other malignant tumors within the past 5 years, excluding cured cervical carcinoma in situ and non-melanoma skin cancer.
Pregnancy or lactation, and patients of childbearing potential who refuse to use adequate contraception during the course of this study.
Prior participation in other studies within 30 days prior to the administration of the first dose of the investigational drug.
Patients who are deemed to be unsuitable for this study by investigators.